Form 4: Eli Lilly Executive Ilya Yuffa Reports Stock Transactions

Eli Lilly's EVP and President of International, Ilya Yuffa, acquired 4,790 shares of common stock and 3,269 restricted stock units on February 12, 2024.

Summary

• Ilya Yuffa, an Executive Vice President at Eli Lilly, reported transactions involving the company's stock.
• On February 12, 2024, Mr. Yuffa acquired 4,790 shares of common stock at a price of $737.26 per share.
• He also acquired 3,269 restricted stock units, each representing a contingent right to receive one share of Eli Lilly common stock.
• Following these transactions, Mr. Yuffa directly owns 19,802 shares of common stock and 3,269 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions, which is neutral in sentiment.

Industry Context

This is a routine filing related to executive compensation and stock ownership, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock transactions are a common practice across publicly traded companies, including pharmaceutical giants like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK).
• These companies also use restricted stock units as part of their executive compensation packages.
• The vesting period of the restricted stock units is typical for such grants.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholder sentiment, but are generally considered routine.

Key Dates

Keywords

Eli Lilly, LLY, insider trading, stock acquisition, restricted stock units, executive compensation, Ilya Yuffa